Seifert J K, Morris D L
University of New South Wales, Department of Surgery, St. George Hospital, Kogarah, Sydney, Australia.
Ann Surg. 1998 Aug;228(2):201-8. doi: 10.1097/00000658-199808000-00009.
To establish the prognostic importance of different patient and tumor characteristics in cryotherapy for liver metastases from colorectal cancer.
Hepatic cryotherapy has been used as a treatment of nonresectable liver metastases from colorectal cancer in almost 1000 patients worldwide, and its safety and efficacy are well established. However, tumor eventually recurs in most patients and they die of their disease. The knowledge of prognostic factors would allow the selection of patients who are more likely to benefit from this treatment and patients who may need additional treatment.
Between April 1990 and May 1997, 195 patients were treated with hepatic cryotherapy. Out of this group, the authors identified 116 patients with colorectal cancer who received cryotherapy for ablation of liver metastases. Survival was estimated with the Kaplan-Meier method, using the log-rank test for univariate analysis for significance of possible prognostic factors. For multivariate analysis, a Cox regression was used.
One patient (0.9%) died of postoperative myocardial infarction. The total perioperative morbidity rate was 27.6%. Median survival and the 5-year survival rate were 26 months and 13.4%. The following factors were identified as independently associated with a favorable outcome: low presurgical serum level of carcinoembryonic antigen (CEA), small (< or =3 cm) diameter of cryoablated metastases, absence of untreated extrahepatic disease at laparotomy, absence of nodal involvement at primary resection, complete cryotreatment, synchronous development of liver metastases, and good or moderate differentiation of the primary tumor. Although univariate analysis suggested a favorable prognosis in patients who did not receive blood transfusion during surgery and patients younger than 51 years, this was not confirmed in multivariate analysis. In addition, normalization of the serum CEA level after treatment was an important prognostic marker in the subgroup of patients with elevated serum CEA levels before surgery.
Hepatic cryotherapy is a safe and effective treatment option for patients with nonresectable liver metastases from colorectal cancer, with promising results regarding survival. The prognostic factors established in this series may allow better patient selection to improve the outcome in suitable patients.
确定不同患者及肿瘤特征在结直肠癌肝转移冷冻治疗中的预后重要性。
肝冷冻治疗已在全球近1000例患者中用于治疗不可切除的结直肠癌肝转移,其安全性和有效性已得到充分证实。然而,大多数患者的肿瘤最终会复发,患者死于该疾病。了解预后因素有助于选择更可能从该治疗中获益的患者以及可能需要额外治疗的患者。
1990年4月至1997年5月期间,195例患者接受了肝冷冻治疗。在该组患者中,作者确定了116例接受冷冻治疗以消融肝转移灶的结直肠癌患者。采用Kaplan-Meier法估计生存率,使用对数秩检验进行单因素分析以确定可能的预后因素的显著性。多因素分析采用Cox回归。
1例患者(0.9%)死于术后心肌梗死。围手术期总发病率为27.6%。中位生存期和5年生存率分别为26个月和13.4%。以下因素被确定为与良好预后独立相关:术前血清癌胚抗原(CEA)水平低、冷冻消融转移灶直径小(≤3 cm)、剖腹手术时无未治疗的肝外疾病、原发灶切除时无淋巴结受累、完全冷冻治疗、肝转移同步发生以及原发肿瘤为高分化或中分化。尽管单因素分析表明手术期间未输血的患者和年龄小于51岁的患者预后良好,但多因素分析未证实这一点。此外,治疗后血清CEA水平正常化是术前血清CEA水平升高患者亚组中的一个重要预后指标。
肝冷冻治疗是不可切除的结直肠癌肝转移患者的一种安全有效的治疗选择,在生存方面有良好的结果。本系列确定的预后因素可能有助于更好地选择患者,以改善合适患者的治疗结果。